FDA expands indication for schizophrenia med; First FDA-approved injectable for double chin launches;

> The FDA allowed Otsuka's schizophrenia-fighting Abilify Maintena to be injected into the the deltoid muscle of the arm, giving it a second administration sight in addition to the gluteus. More

> Ocean Drive Plastic Surgery just launched the first FDA-approved injectable for double chin. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.